NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

Doc logic, I totally agree with you and have been posting about that. I think there is a possibility that some in the 35 group correspond to patients that were initially thought to be recurrent, so received DCVax L and benefited from it. And then it was realized that they were SOC pseudoprogressors, so they were not included in the rGBM arm.

As you say:

Any patient not truly recurring would be removed from the defined rGBM group

And I think what you mention here could be key for those patients and for the trial:

They would also have received L at the exact best time for long term benefit